Longeveron (LGVN) Free Cash Flow (2020 - 2026)
Longeveron (LGVN) recorded quarterly Free Cash Flow of -$4.4 million in Q1 2026, up 17.48% quarter-over-quarter from -$5.3 million in Q4 2025, and up 7.49% on a YoY basis from -$4.1 million in Q1 2025.
Longeveron (LGVN) Free Cash Flow (2020 - 2026) Analysis & Trends
Longeveron's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$4.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.49% year-over-year to -$4.4 million; the TTM figure through Mar 2026 stood at -$18.5 million (down 14.81% YoY), while the FY2025 annual figure was -$18.9 million, down 30.07% from the prior year.
- Free Cash Flow was -$4.4 million for Q1 2026 at Longeveron, up from -$5.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$2.4 million in Q4 2022 to a low of -$5.9 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$4.2 million across 5 years, with a median of -$4.4 million in 2026.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow slumped 94.52% in 2022, then jumped 47.33% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$2.4 million in 2022, then slumped by 75.27% to -$4.2 million in 2023, then rose by 18.63% to -$3.4 million in 2024, then sank by 56.41% to -$5.3 million in 2025, then rose by 17.48% to -$4.4 million in 2026.
- The last three Free Cash Flow figures came in at -$4.4 million (Q1 2026), -$5.3 million (Q4 2025), and -$5.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -4.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.37 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -5.11 Mn |
| Sep 30, 2025 | -5.11 Mn |
| Jun 30, 2025 | -3.76 Mn |
| Jun 30, 2025 | -3.76 Mn |
| Mar 31, 2025 | -4.72 Mn |
| Mar 31, 2025 | -4.72 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.27 Mn |
| Sep 30, 2024 | -3.27 Mn |
| Jun 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -4.76 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -4.16 Mn |
| Dec 31, 2023 | -4.16 Mn |